Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

Product information

CAS Number: 64790-15-4

Molecular Weight: 1352.51

Formula: C61H89N15O18S

Chemical Name: 2-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-aminopropanamido)-4-carbamoylbutanamido]-3-carboxypropanamido}-3-phenylpropanamido)-3-methylbutanamido]-4-carbamoylbutanamido}-3-(1H-indol-3-yl)propanamido)-4-methylpentanamido]-4-(methylsulfanyl)butanamido}-3-carbamoylpropanamido)-3-hydroxybutanoic acid

Smiles: CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC1C=CC=CC=1)C(=O)NC(C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC1=CNC2=CC=CC=C12)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(O)=O

InChiKey: SVHJFTNFNMWDBS-UHFFFAOYSA-N

InChi: InChI=1S/C61H89N15O18S/c1-29(2)23-40(55(87)68-39(21-22-95-7)54(86)73-43(26-47(65)80)59(91)76-50(32(6)77)61(93)94)70-56(88)42(25-34-28-66-36-16-12-11-15-35(34)36)72-53(85)38(18-20-46(64)79)69-60(92)49(30(3)4)75-58(90)41(24-33-13-9-8-10-14-33)71-57(89)44(27-48(81)82)74-52(84)37(17-19-45(63)78)67-51(83)31(5)62/h8-16,28-32,37-44,49-50,66,77H,17-27,62H2,1-7H3,(H2,63,78)(H2,64,79)(H2,65,80)(H,67,83)(H,68,87)(H,69,92)(H,70,88)(H,71,89)(H,72,85)(H,73,86)(H,74,84)(H,75,90)(H,76,91)(H,81,82)(H,93,94)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29).

In Vivo:

Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein.

Products are for research use only. Not for human use.